February 6th 2023
Takhyzro is the first therapy to prevent attacks of hereditary angioedema (HAE) in children ages to 2 to under 6.
February 6th 2023
Zuranolone is a rapid-acting neuroactive steroid that can take effect in 14 days to treat patients with major depressive disorder and postpartum depression. The FDA has assigned a PDUFA action date of Aug. 5, 2023.
February 4th 2023
The products may be ineffective, unsafe and could prevent a person from seeking an appropriate diagnosis.
February 3rd 2023
Trodelvy has been recommended as a preferred treatment for metastatic HR+/HER2- breast cancer by the National Comprehensive Cancer Network.
February 3rd 2023
Tezspire is a biologic that specifically targets the inflammation associated with asthma.